AMG 510 + Docetaxel
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Trial Timeline
Jun 4, 2020 → Feb 25, 2026
NCT ID
NCT04303780About AMG 510 + Docetaxel
AMG 510 + Docetaxel is a phase 3 stage product being developed by Amgen for KRAS p, G12c Mutated /Advanced Metastatic NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT04303780. Target conditions include KRAS p, G12c Mutated /Advanced Metastatic NSCLC.
What happened to similar drugs?
0 of 1 similar drugs in KRAS p, G12c Mutated /Advanced Metastatic NSCLC were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04303780 | Phase 3 | Active |
Competing Products
20 competing products in KRAS p, G12c Mutated /Advanced Metastatic NSCLC